Experimental Drug Shows Promise in Treating Alzheimer's Disease
An experimental drug shows promise in treating Alzheimer’s disease by preventing inflammation and removing abnormal protein clumps in the brain that are associated with the disease. A key characteristic of Alzheimer’s disease is the development of abnormal protein clumps called amyloid plaques and tangled bundles of fibers in the brain. These changes cause inflammation in the brain and damage to the neurons. This progressive damage leads to memory loss, confusion and dementia. The new drug, known as NTRX-07, appears to decrease this inflammation in the brain, while preserving neurons and regenerative cells in the brain. “This drug may reduce inflammation in the brain, which is linked to Alzheimer’s disease,” said lead researcher Mohamed Naguib, MD, a physician anesthesiologist in the Department of General Anesthesiology at the Cleveland Clinic and professor of anesthesiology at the Cleveland Clinic Lerner College of Medicine. “NRTX-07 uses a different mechanism than many other Alzheimer’s drugs currently available, as it targets the cause of the disease, not just the symptoms.” Click here to read more.
Winter Clinics for Cranial and Spinal Surgery
Feb. 25, 2018 - Mar. 1, 2018; Snowmass Village, Colo.
69th Southern Neurosurgical Society Annual Meeting
Feb. 28, 2018 - Mar. 3, 2018; San Juan, PR
Second International Brain Mapping Course
April 26-27, 2018; New Orleans
2018 AANS Annual Scientific Meeting
April 28-May 2, 2018; New Orleans
2018 American Society for Stereotactic and Functional Neurosurgery Biennial Meeting
Jun. 2, 2018 - Jun. 5, 2018; Denver